GlaxoSmithKline Plc expects to deliver sales growth of 5-7% at constant exchange rates this year and a double-digit increase in adjusted operating profit as it repositions itself as a pure biopharmaceutical enterprise. This will follow the demerger of its jointly-owned consumer healthcare business at mid-year. GSK owns 68% of the business, while Pfizer Inc has 32%.
